Penumbra

Penumbra makes specialized medical tools that help doctors remove dangerous blood clots from the body. These devices clear blockages in the brain, lungs, and limbs to prevent strokes and other serious health problems. The company serves patients by providing simple and fast ways to restore blood flow through the veins and arteries.

What Penumbra Makes

• Thrombectomy Products: Systems used to surgically remove blood clots from head to toe; generated $947.9 million in 2025 revenue.
• Embolization Devices: Detachable metal coils used to fill and seal off weak spots in blood vessels, such as aneurysms; generated $455.7 million in 2025 revenue.
• Access Tools: Flexible tubes called catheters that help doctors reach difficult areas inside the brain and body; part of the embolization and access category.
• Neurosurgical Tools: Specialized evacuation devices used to remove fluid or tissue from the brain during surgery.

Strategic Moves and Growth

• Entered a merger agreement with Boston Scientific Corporation in January 2026 to be acquired for approximately $14.5 billion.
• Launched the Lightning Flash 3.0 system in 2025, which uses computer algorithms to detect blood clots more accurately.
• Introduced Lightning Bolt 12 and Lightning Bolt 6X in 2025 to provide faster clot removal in smaller vessels.
• Exited the immersive healthcare business in 2024 to focus resources on the core thrombectomy and vascular markets.
• Expanded manufacturing capabilities in 2025 by entering agreements to build a new production facility in Costa Rica.

What Makes the Company Stand Out

The company operates a highly integrated innovation process that allows it to develop and manufacture nearly all products in-house at its California facilities. This setup supports rapid technical updates and helps maintain strict quality control through its own specialized engineering teams.

A Look at the Numbers

• Total revenue reached $1.4 billion for the year ended December 31, 2025, an increase of 17.5% from the previous year.
• Operating income rose to $189.2 million in 2025, up significantly from $9.3 million in 2024.
• Net income hit $47.3 million in Q4 2025, representing a 40.6% increase over the same period in 2024.
• Free cash flow grew to $68 million in Q4 2025, up 48.8% year-over-year.
• The company increased its global workforce to 4,700 employees by the end of 2025 to support its expanding product lines.

The Bottom Line

Penumbra has shifted from a specialized neurovascular firm into a broad leader in mechanical blood clot removal. Its pending merger with Boston Scientific marks a transition toward integration into a larger global medical technology platform.